 Check-Cap Ltd. the Company or Check-Cap NASDAQ: CHEK, NASDAQ: CHEKZ, a clinical stage medical diagnostics company advancing the development of C-Scan, the first and only preparation-free screening test to detect polyps before they transform into colorectal cancer, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Companys ordinary shares, at a purchase price of 0.60 per share, in a registered direct offering. Check-Cap has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 7,500,001 ordinary shares. The offering is expected to close on or about May 4, 2020, subject to satisfaction of customary closing conditions. 